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Based on small numbers, recent reports
from 3 randomized trials have consis-
tently demonstrated more hematologic
malignancies in patients treated with lena-
lidomide as maintenance (vs placebo).
This fact has prompted concern and high-
lighted the association between multiple
myeloma and second malignancies. Fur-
thermore, an excess of acute myeloid
leukemia (AML) and myelodysplastic syn-
dromes (MDS) after multiple myeloma has
been known for over 4 decades. Most
prior studies have been restricted be-
cause of small numbers of patients, inad-
equate follow-up, and limitations of ascer-
tainment of second malignancies.
Although the underlying biologic mecha-
nisms of AML/MDS after multiple my-
eloma are unknown, treatment-related fac-
tors are presumed to be responsible.
Recently, an excess risk of AML/MDS was
found among 5652 patients with IgG/IgA
(but not IgM) monoclonal gammopathy of
undetermined significance, supporting a
role for disease-related factors. Further-
more, there is evidence to suggest that
polymorphisms in germline genes may
contribute to a person’s susceptibility to
subsequent cancers, whereas the poten-
tial influence of environmental and behav-
ioral factors remains poorly understood.
This review discusses current knowledge
regarding second malignancies after mul-
tiple myeloma and gives future directions
for efforts designed to characterize under-
lying biologic mechanisms, with the goal
to maximize survival and minimize the
risk for second malignancies for indi-
vidual patients. (Blood. 2012;119(12):
2731-2737)
Introduction
After decades of virtually no progress, multiple myeloma survival
has improved significantly in the last 10 years, in younger patients
even 2- to 3-fold.1-3 Indeed, multiple myeloma has seen more
remarkable progress in treatment and patient outcomes than any
other cancer in the last decade. With improvements in survival, a
relatively new clinical challenge that has emerged is the risk of
second malignancies. This pattern of increase in second malignan-
cies has been observed in other cancers with available curative
therapies and favorable outcomes. Survivors of testicular cancer
are at up to 3-fold higher risk of developing a second malignancy
than the general population.4 Survivors of Hodgkin lymphoma
have more than 3 times greater risk of solid tumors. Fifteen years
after diagnosis, the cumulative mortality from second malignancies
exceeds cumulative mortality from Hodgkin lymphoma.5,6 In the
United States alone, the number of cancer survivors has tripled
since 1971 and is growing by 2% each year; cancer survivors
constitute 3.5% of the United States population.7 Indeed, second-
or higher-order cancers account for 18% of incident cancers in the
United States, making them the third most common cancer
diagnosis.7 Based on the National Cancer Institute Surveillance,
Epidemiology and End Results (NCI SEER) database, compared
with the general population, cancer survivors have a 14% increased
risk of developing a malignancy.7
In the late 1960s, based on a restricted number of patients, an
association between multiple myeloma and leukemia was first
reported.8-10 In 1979, based on a clinical trial, including 364 mul-
tiple myeloma patients, Bergsagel et al reported a greater than
expected incidence of all forms of acute leukemia for patients
treated with low-dose melphalan containing combinations of
alkylating agents.11 In the era where low-dose melphalan was the
mainstay of multiple myeloma therapy, because of poor overall
survival rates, the absolute number of multiple myeloma patients at
risk for acute leukemia was small. Although the use of low-dose
melphalan declined substantially with the advent of high-dose
melphalan followed by autologous stem cell transplantation (ASCT)
in the late 1980s, melphalan-based combinations continue to be
used in ASCT-ineligible patients.12 In the posttransplant era,
several studies found that conventional chemotherapy preceding
the transplant played a greater role in the development of myelodys-
plastic syndromes (MDSs) and acute leukemia than myeloablative
therapy used in conjunction with ASCT. In the last decade, agents
with new mechanisms of action (such as thalidomide, bortezomib,
and lenalidomide), and continuing improvements in supportive
care have further improved response rates, progression-free sur-
vival, and overall survival in multiple myeloma. Recent prelimi-
nary reports of increased risk of second malignancies, predomi-
nantly MDS/acute leukemia, with lenalidomide have further
highlighted this challenge in multiple myeloma patients.
Larger population-based studies support and expand on findings
from smaller clinical studies showing that multiple myeloma
patients have an increased risk of developing MDS/acute leukemia
compared with the general population.13-15 Based on the NCI SEER
database, among 23 838 multiple myeloma diagnosed between
1973 and 2000, leukemia accounted for the largest cancer excesses,
with acute myeloid leukemia (AML) constituting 80% of leukemia
cases. Increased risks were also noted for Kaposi sarcoma and
chronic myeloid leukemia.7 However, the overall risk of develop-
ing any type of a subsequent primary cancer was not increased. The
increased risk of developing a new malignancy was limited to
persons diagnosed with multiple myeloma at ages younger than
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70 years; subsequent cancer risk did not differ by sex, race, or
initial therapy. It is to be noted that NCI SEER database did not
capture information on MDS until the introduction of International
Classification of Diseases for Oncology, 3rd edition in 2001.16
Overall, based on a restricted number of investigations, most
prior studies implicate treatment-related factors as the main
contributing factor to development of second malignancies after
multiple myeloma. However, the lack of molecular markers that are
specific for therapy-induced cancer and inability to compare
different treatment durations in a clinical trial setting limits our
ability to define the impact of prior therapy in the etiology of a
second malignancy. Indeed, it seems reasonable to propose that
second malignancies in multiple myeloma may not be attributable
solely to prior treatment. Rather, the development of second
malignancies may reflect combinations of influences, including
treatment-related, multiple myeloma-related, host-related, environ-
mental, and behavioral factors (Figure 1).17 In this article, we
review and discuss our current understanding of second malignan-
cies after multiple myeloma.
Treatment-related factors
The effects of treatment-related factors, including oral alkylating
therapy on the development of malignancies after multiple my-
eloma, have been assessed (Table 1).11,13,14,18-22 Bergsagel et al
conducted the first prospective clinical study evaluating the value
of a combination of 3 alkylating agents in the treatment of multiple
myeloma: melphalan, cyclophosphamide, and carmustine. In their
study, the observed versus expected incidence of all forms of acute
leukemia was increased for all age groups.11 Indeed, the patterns
are quite similar to investigations focusing on non-Hodgkin
lymphoma23 and Hodgkin lymphoma,24 showing MDS/acute leuke-
mia to be associated with long-term alkylating therapy, and with a
cumulative dose-response effect. Since these early observations,
treatment-related factors, including melphalan, have been consid-
ered the main cause of excess of MDS/acute leukemia in multiple
myeloma patients, although the biologic mechanisms were not well
defined. In a subsequent study, Cuzick et al reported a positive
association between the duration of melphalan treatment and the
subsequent risk of developing leukemias.22 In that study, the
cumulative dose of melphalan given up to 3 years before leukemia
diagnosis was reported to be the most important determinant of
risk. However, this association has not held true in all studies. For
example, a retrospective cohort study from the Finnish Leukemia
Group found no significant association between the duration and
cumulative doses of melphalan and AML risk subsequent to
multiple myeloma.13 In addition, in another study, cyclophospha-
mide was found to be less leukemogenic than melphalan.22,24
After the introduction of high-dose melphalan/ASCT, several
studies addressed the relative contribution of myeloablative therapy
used in conjunction with ASCT and conventional chemotherapy
preceding the transplant toward development of MDS/AML.
Govindarajan et al21 compared 2 groups of patients with different
exposure to alkylating agents preceding transplant. Group 1 had
received no more than 1 cycle of standard alkylating therapy and
group 2 had significantly prolonged exposure to chemotherapy,
including alkylators before transplant. Both groups were treated
with 1 course of high-dose cyclophosphamide (CTX) to mobilize stem
cells followed by 2 courses of high-dose melphalan with autologous
stem cell support. Despite a longer follow-up (36 months vs 29 months;
P .05), none of the patients in group 1 developed MDS, compared
with 7 patients in group 2.21 Other studies also demonstrated that
conventional chemotherapy before ASCT is a more likely contrib-
uting factor of MDS/acute leukemia, rather than pretransplant
myeloablative therapy, maintenance therapy, or additional treat-
ment after transplantation.19 Furthermore, a recent population-
based study, based on 8740 myeloma patients diagnosed in Sweden
(1986-2005), found the rates of MDS/AML before and after
introduction of high-dose melphalan/ASCT to be very similar,
further supporting that the introduction of high-dose melphalan as
pretransplant myeloablative therapy has not increased the risk of
subsequent MDS/AML, beyond that of lower doses of melphalan.15
Radiotherapy may also have a potential role in development of
second malignancies after multiple myeloma. Indeed, approxi-
mately 40% of patients with multiple myeloma may require
treatment with radiotherapy at some time during their illness.25
Studies focusing on Hodgkin lymphoma and breast cancer have
found an increased risk of second malignancies after radiotherapy,
with a dose-response relationship between risk of second malig-
nancy and radiation dose to the surrounding tissues, including the
bone marrow.17,26,27 For example, malignancies associated with
locoregional radiation for breast cancer include sarcomas, lung and
esophageal cancers, and AML.27-29 At this time, to our knowledge,
there is limited information on the association between radio-
therapy and risk of subsequent malignancies in multiple myeloma.
Maintenance therapy has been evaluated in relation to risk of second
malignancies in 3 recently reported multicenter randomized phase
3 trials (IFM 2005-02, CALGB 100104, and MM-015)30-32 (Table 1).
IFM 2005-02 and CALGB 100104 explored the role of lenalidomide
maintenance therapy after high-dose melphalan/ASCT.30,31 In both
trials, lenalidomide at a dose of 10 to 15 mg given within 3 to 6 months
of autologous transplantation was compared with placebo until disease
progression. Unlike CALGB 100104, patients in the IFM trial received
lenalidomide induction for 2 months before maintenance dosing, had a
longer follow-up, and no crossover was permitted to the lenalidomide
arm at progression.32 In the IFM 2005-02 and CALGB 100104 trials,
Figure 1. Proposed model of second malignancies after multiple myeloma.
Examples for the categories include the following: (1) alkylating agents, immunomodu-
latory agents, autologous stem cell transplant, and radiation; (2) molecular subtypes
of disease, biclonal disease, and bone marrow microenvironment; (3) polymorphisms
in germline genes (eg, drug-metabolizing genes, erythropoietin promoter gene),
chronic antigenic stimulation, and genetic susceptibility with other malignancies;
(4) occupation, pesticides, and chlorinated solvents; and (5) tobacco, obesity,
alcohol, and diet.
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5.5% and 6.5% of lenalidomide-treated patients developed second
malignancies compared with 1% and 2.5% in the respective control
arms. The second malignancies reported include AML/MDS, Hodgkin
lymphoma, B-cell acute lymphoblastic leukemia, colon, prostate, breast,
and esophageal cancers. MM-015 evaluated maintenance lenalidomide
after combination of lenalidomide with melphalan and prednisone (MP)
versus fixed MP duration regimens in 65-year-old (or older) transplant-
ineligible patients with newly diagnosed multiple myeloma.32 This
study also found an increase in the number of second cancers in
lenalidomide-treated patients, notably AML, which was associated with
complex baseline cytogenetics: 2 cases each were observed in the
lenalidomide-treated arms and none in the MP arm (0.7% vs 0%). The
standardized incidence ratio for AML in the MP-lenalidomide followed
by lenalidomide maintenance and placebo maintenance was 4.46 and
4.65, respectively, compared with the NCI SEER database.32 At this
time, IFM 2005-02 and MM-015 have demonstrated a progression-free
survival benefit, although there was no improvement in overall survival
for patients who received lenalidomide. CALGB 100104 demonstrated
an overall survival improvement in lenalidomide-treated patients with
an overall survival rate at 23 months of 90% in the continuous
lenalidomide arm compared with 83% in the placebo arm (P .018),
despite 80% of patients crossing over to receive continuous lenalido-
mide.31 Maintenance lenalidomide was discontinued in the IFM 2005-02
trial, whereas patients on the other trials continue to receive lenalido-
mide with enhanced monitoring while an ongoing safety review is
completed.35
Among patients with relapsed/refractory multiple myeloma,
2 retrospective studies have evaluated the role of lenalidomide in
relation to the risk of second malignancies.33,34 Based on 230 re-
lapsed/refractory multiple myeloma patients treated with lenalido-
mide-based regimens, Reece and Goswami found MDS/AML in
2.6% (6 patients) at a median of 76 months from the time of
diagnosis of multiple myeloma and 61 months from the time of
initiation of lenalidomide.33 Although the prior exposure to alkylat-
ing agents was similar in both groups, patients who developed
AML/MDS were older (median, 68 years; range, 54-76 years; vs
median, 61 years; range, 32-80 years), less likely to have had
high-dose melphalan/ASCT (2, 33%; vs 149, 82%) and had longer
Table 1. Selected studies focusing on second malignancies after multiple myeloma
Reference Study design (study period)
No. of
patients
Any second
malignancy, %
Multiple myeloma to
second malignancy,
median time
Hematologic malignancy,
n (%)
Solid tumor, n
(%)
15 Population-based registry study
(1986-2005)
8740 6.6 45.3 mo (AML/MDS) 69 (0.8) 508 (5.8)
18 Retrospective study, single institution
(1997-2008)
589 3 35 mo 6 (1.0) 12 (2.0)
30* Randomized phase 3 trial,
maintenance lenalidomide vs
placebo after high-dose
melphalan/ASCT
614 5.5 (lenalidomide
maintenance);
1 (placebo)
44 mo Lenalidomide maintenance:
† 11 (1.8); placebo arm:†
3 (0.5)
Lenalidomide
maintenance:†
12 (2.0);
placebo arm:†
3 (0.5)
31* Randomized phase 3 trial,
maintenance lenalidomide vs
placebo after high-dose
melphalan/ASCT
460 6.5 (lenalidomide
maintenance);
2.6 (placebo)
17.5 mo after ASCT Lenalidomide
maintenance:† 8 (1.7);
placebo arm:† 0 (0)
Lenalidomide
maintenance:†
10 (2.2);
placebo arm:†
4 (0.9)
32* Randomized phase 3 trial,
maintenance lenalidomide vs
placebo after low-dose
melphalan/prednisone with or
without lenalidomide
459 3.9 (lenalidomide
maintenance);
1.3 (placebo)
25 mo MPR-R arm:† 7 (1.5); MPR
arm:† 5 (1.1); MP arm:†
1 (0.2)
MPR-R: 5 (1.1);†
MPR:† 4
(0.9); MP:† 3
(0.7)
19 Retrospective study, single institution
(1989-2007)
2418 1.1 NR 26 (1.1) NR
20 Retrospective study, single institution
(1996-2005)
82 12.2 50 mo 10 (12.2) NR
14 Population-based registry study
(1958-1996)
8656 5.5 2.9 y 83 (1.0) 392 (4.5)
13 Retrospective study based on
patients from clinical trials (1979-
1985)
432 9.2 37 mo (solid tumors)
56 mo (acute
leukemia)
17 (3.9) 23 (5.3)
21 Prospective study (NR) 188 3.8 63 mo 7 (3.8) NR
22 Retrospective study based on
patients from clinical trials (1964-
1975)
648 1.9 82 mo 12 (1.9) NR
11 Prospective study (1973-1977) 364 3.8 NR 14 (3.8) NR
10 Case series (1965-1966) 3 NA 45 mo 3 (NA) NR
71 Case series (1950-1966) 6 NA 10 y 1 (NA) NR
8 Retrospective study, multi-institution
(1932-1963)
310 2.3 NR 7 (2.3) NR
MPR-R indicates melphalan/prednisone, revlimid (lenalidomide), with revlimid maintenance; MPR, melphalan/prednisone, revlimid (lenalidomide), without revlimid
maintenance; MP, melphalan/prednisone, without revlimid maintenance; NR, not reported; and NA, not applicable.
*These results come from interim analyses presented at the American Society of Hematology meeting, Orlando, FL, December 4-7, 2010.
†Updated numbers from presentations at the International Myeloma Workshop in Paris, France, May 3-6, 2011. At this time, the final analyses and written reports have not
yet been published.
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duration of treatment with lenalidomide (median number of cycles,
21; range, 9-35; vs median number of cycles, 9; range, 1-50.33 A
posthoc analysis of pooled data from phase 3 MM-009 and
MM-010 trials revealed 2 MDS, 8 solid tumors, and no leukemias.
Using NCI SEER data, no increase in incidence of solid tumors was
noted compared with the general population.34
In parallel with the aforementioned studies reporting on lenalido-
mide maintenance and excess MDS/AML development in multiple
myeloma, other investigations have been evaluating the role of
lenalidomide treatment in the setting of MDS. For example, a
recent study reported that lenalidomide used as treatment for 5q
MDS was not associated with AML progression.35
Taken together, mostly based on small numbers, prior studies
have found various types of therapies (eg, oral alkylating therapy,
myeloablative therapy used in conjunction with ASCT, radio-
therapy, and lenalidomide) to be associated with an excess of
second malignancies after multiple myeloma. Yet the exact under-
lying mechanisms remain to be determined, and several studies to
elucidate the underlying mechanisms are ongoing.
Multiple myeloma-related factors
Although presenting with the same histologic picture, multiple
myeloma displays a broad molecular range characterized by
subgroups with unique gene expression profiles, which correlate
with clinical characteristics and patient survival. Moreover, addi-
tional molecular events, including epigenetic changes and activa-
tion of molecular pathways, occur during multiple myeloma
progression and treatment.36,37
In a recent population-based study from Sweden, based on
5652 patients with multiple myeloma precursor disease, monoclo-
nal gammopathy of uncertain significance (MGUS), an 8-fold
increased risk of developing MDS/AML was observed.15 The
elevated risk was confined to those with IgG/IgA (and not IgM)
MGUS. Interestingly, MGUS patients with M-protein concentra-
tions more than 1.5 g/dL (standardized incidence ratio 11.12)
had higher risk than those with less than or equal to 1.5 g/dL
(standardized incidence ratio 4.67), suggesting that more active
precursor disease has similar baseline risk for AML/MDS to that of
active multiple myeloma.15 Overall, these observations are impor-
tant in that they support a role for disease-related factors in
MDS/AML after multiple myeloma and raise the question whether
underlying molecular heterogeneities in multiple myeloma may be
related to the risk of developing second malignancies. It is possible
that certain molecular multiple myeloma subgroups are at a higher
risk than others. For example, a potential mechanism could be
selective pressure (ie, a pre-existing nondominant clone, unrespon-
sive to treatment) leading to an increased susceptibility to develop-
ing second malignancies. A better understanding of underlying
molecular mechanisms across multiple myeloma subgroups and
risk of second malignancy will form the basis for modification and
targeting therapies to specific subgroups, with the overall goal to
minimize the risk of second malignancies.
Host-related factors
Although we lack large well-designed studies at this time, based on
work done on other cancer types, it seems reasonable to propose
that host-related (including both genetic and nongenetic) factors
may play a role in the development of second malignancies after
multiple myeloma. Indeed, it has been estimated that genetic
variations can account for up to 95% of variability in drug
disposition and effects.38 In addition to drug disposition and
response to treatment, polymorphisms in genes encoding drug-
metabolizing enzymes, DNA repair pathways, drug transporters,
and targets may also contribute to a person’s susceptibility for
subsequent malignancies as well.17,39 For example, decreased
production of glutathione S-transferase enzymes, GSTM1 and
GSTT1, results from polymorphisms of respective genes, which
may be associated with an increased MDS risk in the presence of
environmental mutagens and/or carcinogen exposure.40 Similarly,
polymorphisms in genes that regulate cellular responses to DNA
damage can affect the risk of developing MDS/AML, presumably
by influencing the survival of hematopoietic cells with proleukemo-
genic mutations.41 Nongenetic host factors, which can modulate
treatment effects, include age, race, organ function, concomitant
therapy, drug interactions, and myeloma itself.
Two studies (n 2418 and 82) observed that patients who
eventually develop MDS or MDS-associated cytogenetic abnormali-
ties have a lower CD34 yield at collection, suggesting a preexisting
marrow abnormality probably a result of host or host-myeloma
interaction.11,20 Similar observations have been reported in Hodg-
kin lymphoma and non-Hodgkin lymphoma, where cytogenetic
abnormalities observed at the diagnosis of MDS/AML were
already present in the morphologically normal pretransplant bone
marrow.42,43 Furthermore, the bone marrow microenvironment may
be important in the pathogenesis of MDS/AML. MGUS and
multiple myeloma are dependent on mutual interactions with cells
and extracellular components of the bone marrow for survival and
growth. Interactions of multiple myeloma cells with the bone
marrow microenvironment activate a pleiotropic proliferative and
antiapoptotic cascade, including the NFB signaling pathway
resulting in multiple myeloma cell growth, survival, drug resis-
tance, and migration. Moreover, many of the growth factors
secreted by multiple myeloma and bone marrow stromal cells
stimulate osteoclastogenesis and angiogenesis.36 It is conceivable
that the resultant changes in bone marrow microenvironment may
play a role in development of MDS/AML after multiple myeloma.
Chromosome 5 abnormalities and clinical phenotype consistent
with 5q syndrome have been described in some patients with
lenalidomide-associated MDS.33,44 5q syndrome is a disorder of
the human hematopoietic stem cell with a combined lympho-
myeloid potential and is known to represent an early event in MDS
pathogenesis. Lenalidomide is approved for use in selected patients
with 5q with or without additional cytogenetic abnormalities.
Rare and phenotypically distinct 5q hematopoietic stem cells that
are selectively resistant to lenalidomide have been identified in
MDS patients during complete clinical and cytogenetic remis-
sion.45,46 It is plausible that a subclone of lenalidomide-resistant
hematopoietic stem cells may expand during treatment, resulting in
MDS/AML. 5q has also been described as part of a complex
karyotype in secondary leukemias.47,48
Recently, we found the G/G phenotype of single nucleotide
polymorphism rs1617640 in the erythropoietin promoter gene,
which is associated with decreased erythropoietin expression, to be
more common (27% vs 12%) in multiple myeloma patients who
developed MDS compared with patients who did not.49 This
suggests a role for susceptibility genes in the development of
second malignancies after multiple myeloma. These results need to
be confirmed in larger studies on a wider panel of genes.
To better understand the role of host genetics in defining
susceptibility to second malignancies, it is important to identify
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susceptibility loci and alleles and establish how these interact with
exposure to affect cellular response to therapeutic exposures and
the subsequent risk of disease.41 Genome-wide association studies
and gene expression microarray analysis of groups of patients with
and without second malignancies have identified several candidate
single nucleotide polymorphisms, which are associated with acute
leukemia after other malignancies.50-52 Identifying patients at risk
for second malignancies at the time of diagnosis of multiple
myeloma would enable personalizing treatment and posttherapy
surveillance options to minimize this risk.
Environmental factors
Several proposed environmental risk factors are shared between
multiple myeloma and second malignancies. For cancers that share
etiologic factors with multiple myeloma, the pertinent genetic traits
will probably have low to moderate penetrance and be driven by
multiple gene-environment and gene-gene interactions.17 For ex-
ample, some, but not all, prior studies indicate that exposure to
ionizing radiation, especially at younger ages and at higher doses,
increases the risk of developing multiple myeloma and MGUS in
addition to leukemias, MDS, and solid tumors.53-57 In addition,
prior studies have suggested that exposure to chlorinated solvents
is associated with development of non-Hodgkin lymphoma, leuke-
mia, and multiple myeloma.58,59 Chronic antigen stimulation from
prior autoimmune, infectious, inflammatory, allergic disorders and
immune dysregulation may play a role in pathogenesis of both
multiple myeloma and AML/MDS.60-62 Recently, solid organ
transplant patients receiving immunosuppressive therapy have
been reported to be at risk for the development of AML.63 In
addition, socioeconomic status has been shown to influence
survival in both multiple myeloma and AML, suggesting that
lifestyle factors in these disorders are of importance.64
Behavioral factors
Tobacco use and alcohol intake are causally related to multiple
primary cancers. Multiple myeloma may share behavioral risk
factors with other malignancies and multiple myeloma survivors
exposed to these risk factors at a higher risk of subsequent
malignancies. Interestingly, the commonly proposed behavioral
risk factors (eg, tobacco, alcohol, and diet) for various types of
cancers have not been associated with multiple myeloma.65,66
Nevertheless, obesity has been associated with an increased risk for
both multiple myeloma and MGUS,67,68 and a slightly decreased
risk for multiple myeloma has been reported to be associated with
the consumption of cruciferous vegetable and fish.69
Discussion
Despite being known for several decades, accurate estimates of
incidence and pathogenesis of second malignancies after multiple
myeloma are lacking. Current literature focusing on second
malignancies after multiple myeloma is limited and should be
interpreted with caution. For example, most prior studies are
restricted because of small numbers of patients, inadequate follow-
up, and limitations of ascertainment of second malignancies (Table
2). Largely because of insufficient data and a small number of
studies, most of our current understanding of malignancies after
multiple myeloma is modeled on experiences with other malignan-
cies, such as Hodgkin lymphoma, and emphasizes the role of
treatment.11,19-22 Based on current knowledge, it seems reasonable
to propose that the development of second malignancies after
multiple myeloma, is most likely a multifactorial process. Contrib-
uting factors probably include various multiple myeloma treat-
ments, multiple myeloma-related factors, host-related factors, as
well as environmental and behavioral factors (Figure 1). Early
works in this area and subsequent efforts have focused on the role
of treatment-related factors, such as alkylating agents.11,19-22 Be-
cause of the insufficient data, the role of non–treatment-related
factors remain largely unexplored. For example, based on small
numbers of patients, there are indications that host genetic polymor-
phisms may play a role in pathogenesis of second malignancies.49
In addition, recent population-based data suggest that IgG/IgA
MGUS patients may also be at an increased risk for AML/MDS.15
These results support a role for host- and disease-related factors
and, if validated in larger studies, they set the stage for future
investigations designed to define underlying molecular mecha-
nisms. Other non–treatment-related factors, such as environment
and behavior, are also not well understood.
Based on small numbers, recent reports from 3 randomized
trials have consistently demonstrated more hematologic malignan-
cies in patients treated with lenalidomide as maintenance (vs
placebo).30-32 Further studies are needed to better characterize
underlying mechanisms of these observations. Beyond the underly-
ing biology, the clinical implications of excess of second malignan-
cies in multiple myeloma patients who receive lenalidomide need
to be interpreted in the context of competing risks. On a clinical
note, for most patients, multiple myeloma still remains an incurable
malignancy and, on average, the general risk of dying is substan-
tially higher than the risk of developing a second cancer (Figure
2).70 That being said, although numbers are small, for individual
patients who do develop AML/MDS after multiple myeloma, the
outcomes are devastating. These 2 parallel perspectives (“on
average” vs “individual patients”) highlight the complexity of
clinical medicine in the era of modern therapy and correlative
science. Furthermore, progression-free survival was significantly
prolonged in all 3 studies of lenalidomide maintenance; and in one
of these, the CALGB 100104 trial of lenalidomide maintenance
after high-dose melphalan/ASCT, there was also a significant
overall survival benefit. In summary, these facts are tightly
intertwined, and there are multiple aspects to consider. Although
there are few clear answers available at this time, in our opinion,
clinicians need to discuss the risks and benefits with patients and
stay updated as more data become available. Until we have access
to better knowledge, in our opinion, in circumstances where the
benefit of maintenance therapy in terms of overall survival is not
well established, the risks versus any possible benefit should be
taken more cautiously.
Table 2. Selected study-related factors that may bias the estimated
risk of second malignancies after multiple myeloma
Short-term follow-up
Small sample sizes
Combinations and interactions between multiple drugs
Inadequate control group
Retrospective data collection
Under-reporting by clinicians
Survival difference (person-years) between experimental and surveillance arms
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Future directions
In the context of increasing overall survival in multiple myeloma
and the recently reported increase of second malignancies associ-
ated with use of lenalidomide,30-32 it is imperative that we readdress
the association between multiple myeloma and leukemia, which
was first reported in the late 1960s.8-10 Importantly, because of
inherent problems related to the small number of cases, collabora-
tive efforts are needed to better characterize molecular features of
patients who develop second malignancies after multiple myeloma.
Such efforts would allow us to better define the role of treatment-
and non-treatment–related factors, and how they may influence
each other. Ultimately, we could use such knowledge to identify
high-risk and low-risk patients, and to tailor therapy, with the goal
to maximize survival and minimize the risk for second malignan-
cies for the individual patient.
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